Fosamax

Base Information

• Chemical Name: Fosamax
• CAS No.: 129318-43-0
• Deprecated CAS: 1159882-48-0
• Molecular Formula: C4H13NO7P2.Na
• Molecular Weight: 272.08
• Hs Code.: 2922509090
• ChEMBL ID: CHEMBL675
• NCI Thesaurus Code: C973
• RXCUI: 203152
• Wikidata: Q27259256
• Mol file: 129318-43-0.mol

Synonyms:4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate;Alendronate;Alendronate Monosodium Salt, Trihydrate;Alendronate Sodium;Aminohydroxybutane Bisphosphonate;Fosamax;MK 217;MK-217;MK217

Chemical Property of Fosamax

Chemical Property:

• Melting Point: 119 °C
• Boiling Point: 616.7oC at 760 mmHg
• Flash Point: 326.7oC
• PSA: 180.93000
• LogP: -0.46040
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 5
• Exact Mass: 270.99867000
• Heavy Atom Count: 15
• Complexity: 293

Purity/Quality:

99% ^*data from raw suppliers

sodiumhydrogen(4-amino-1-hydroxy-1-phosphonobutyl)phosphonate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+]
• Recent ClinicalTrials: Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
• Recent EU Clinical Trials: Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metastatic hormonal receptor positive breast cancer (the ADAIDO study, Alendronate after Denosumab and Aromatase Inhibitors Discontinuation in Osteopenic women with breast cancer).
• Recent NIPH Clinical Trials: Study of glucocorticoid-induced osteoporosis prevention in patients with glomerulonephritis
• Drug interactions: 1. Antacids and cathartic agents will often affect the absorption of the drug for containing calcium or other metal ions such as magnesium, iron and so on. 2. Inducing hypocalcemia when in combination with aminoglycosides.
• Description: Alendronate sodium is the fourth bisphosphonate to reach the market for the treatment of postmenopausal osteoporosis. Bisphosphonates are potent inhibitors of bone resorption. They reduce pain and complications due to bone metastases, are effective in Paget's disease and in increasing bone mineral density. These agents bind tightly to hydroxyapatite crystals and are retained on bone resorption surfaces. Local release of the bisphosphonates occurs by acidification during the process of the bone resorption to impair the osteoclasts' ability to resorb bone. Alendronate is more potent than other bisphosphonates such as clodronate, pamidronate, and etidronate and is reported to have no deleterious effects on bone. It has also been shown to reduce hypercalcemia in cancer patients.
• Clinical Use: The second-generation agent alendronate sodium was the first bisphosphonate agent approved by the U.S. FDA for the prevention and treatment of osteoporosis and Paget's disease of the bone and is 1,000-fold more potent than etidronate.